United Therapeutics Corporation (UTHR) Cut to “Hold” at ValuEngine

United Therapeutics Corporation (NASDAQ:UTHR) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a report issued on Friday, September 8th.

A number of other equities research analysts have also recently commented on the company. BidaskClub cut United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Zacks Investment Research cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. UBS AG reissued a “sell” rating and issued a $106.00 price objective on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Finally, Jefferies Group LLC reissued a “sell” rating and issued a $105.00 price objective on shares of United Therapeutics Corporation in a report on Friday, July 14th. Six research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company’s stock. United Therapeutics Corporation presently has a consensus rating of “Hold” and a consensus price target of $134.50.

Shares of United Therapeutics Corporation (UTHR) opened at 120.79 on Friday. United Therapeutics Corporation has a 12-month low of $110.90 and a 12-month high of $169.89. The company has a 50-day moving average price of $128.92 and a 200 day moving average price of $129.77. The company has a market capitalization of $5.25 billion, a P/E ratio of 14.01 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of $3.61 by ($4.86). United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The business had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. During the same quarter last year, the business posted $4.42 earnings per share. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics Corporation will post $10.09 earnings per share for the current fiscal year.

WARNING: “United Therapeutics Corporation (UTHR) Cut to “Hold” at ValuEngine” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://ledgergazette.com/2017/09/17/valuengine-downgrades-united-therapeutics-corporation-uthr-to-hold.html.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,258 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $122.08, for a total value of $153,576.64. Following the sale, the chief executive officer now directly owns 2,327 shares of the company’s stock, valued at $284,080.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 1,247 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $126.40, for a total value of $157,620.80. Following the completion of the sale, the chief executive officer now directly owns 2,316 shares in the company, valued at $292,742.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,198 shares of company stock worth $3,281,816. 7.80% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of UTHR. BlackRock Inc. grew its holdings in United Therapeutics Corporation by 4,222.8% in the first quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock valued at $641,969,000 after purchasing an additional 4,632,287 shares during the period. Wells Fargo & Company MN grew its holdings in United Therapeutics Corporation by 144.0% in the second quarter. Wells Fargo & Company MN now owns 730,634 shares of the biotechnology company’s stock valued at $94,785,000 after purchasing an additional 431,210 shares during the period. JPMorgan Chase & Co. grew its holdings in United Therapeutics Corporation by 308.6% in the second quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock valued at $64,930,000 after purchasing an additional 378,002 shares during the period. AQR Capital Management LLC grew its holdings in United Therapeutics Corporation by 27.8% in the first quarter. AQR Capital Management LLC now owns 1,736,357 shares of the biotechnology company’s stock valued at $235,068,000 after purchasing an additional 377,395 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of United Therapeutics Corporation by 65.5% in the second quarter. Renaissance Technologies LLC now owns 837,600 shares of the biotechnology company’s stock valued at $108,662,000 after acquiring an additional 331,400 shares in the last quarter.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply